Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin
Launched by IKFE INSTITUTE FOR CLINICAL RESEARCH AND DEVELOPMENT · Dec 17, 2007
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
To demonstrate that reconverting type 2 diabetic patients from insulin treatment to oral treatment using pioglitazone in combination with or without glimepiride is possible without deterioration of blood glucose control.
Primary aim is to maintain glycaemic control (HbA1c) defined as an increase in HbA1c of not more than 0.5 % after 6 months of treatment (visit 7) compared to baseline HbA1c value (screening visit V1).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • type 2 diabetes mellitus
- • insulin therapy \> 1 year
- • residual ß-cell function (C-peptide increase in iv glucagon test)
- • written informed consent
- Exclusion Criteria:
- • type 1 diabetes
- • oral therapy
- • life-threatening disease
- • heart failure (NYHA I-IV)
About Ikfe Institute For Clinical Research And Development
The IKFE Institute for Clinical Research and Development is a leading organization dedicated to advancing medical science through innovative clinical trials. With a commitment to enhancing patient care and treatment outcomes, IKFE specializes in a wide range of therapeutic areas, employing rigorous methodologies and state-of-the-art technologies to ensure the integrity and reliability of research findings. The institute collaborates closely with healthcare professionals, regulatory bodies, and industry partners to facilitate the development of new therapies, ultimately aiming to bring safe and effective treatments to market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mainz, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials